Premium
Serum osteocalcin concentrations in patients with multiple myeloma — correlation with disease stage and survival
Author(s) -
CARLSON K.,
LJUNGHALL S.,
SIMONSSON B.,
SMEDMYR B.
Publication year - 1992
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.1992.tb00514.x
Subject(s) - osteocalcin , medicine , multiple myeloma , endocrinology , bone remodeling , osteoblast , bone disease , gastroenterology , osteoporosis , alkaline phosphatase , biology , enzyme , biochemistry , in vitro
Multiple myeloma affects bone, and enhanced bone resportion is a characteristic finding. In the present study the serum concentration of osteocalcin, serum bone gla‐protein, which is a protein specific for bone turnover and reflects osteoblast activity, was analysed at diagnosis in 48 patients with multiple myeloma. At that time there was a significant relationship between disease stage (Durie‐Salmon) and osteocalcin levels, lower levels being found in patients with more advanced disease. No relationship was found between osteocalcin and serum calcium levels. To date, 33 patients have died. There was a significant correlation between initial osteocalcin levels and patient survival. These findings suggest that serum osteocalcin could be a marker of prognostic significance for survival in multiple myeloma.